Abstract
Pancreatic adenocarcinoma has a five-year survival rate of only 6%, largely because current diagnostic methods cannot reliably detect the disease in its early stages. Reflectance and fluorescence spectroscopies have the potential to provide quantitative, minimally-invasive means of distinguishing pancreatic adenocarcinoma from normal pancreatic tissue and chronic pancreatitis. The first collection of wavelength-resolved reflectance and fluorescence spectra and time-resolved fluorescence decay curves from human pancreatic tissues was acquired with clinically-compatible instrumentation. Mathematical models of reflectance and fluorescence extracted parameters related to tissue morphology and biochemistry that were statistically significant for distinguishing between pancreatic tissue types. These results suggest that optical spectroscopy has the potential to detect pancreatic disease in a clinical setting.
© 2011 OSA/SPIE
PDF ArticleMore Like This
Robert H. Wilson, Malavika Chandra, William Lloyd, James Scheiman, Diane Simeone, Julianne Purdy, Barbara McKenna, and Mary-Ann Mycek
BWB6 Biomedical Optics (BIOMED) 2010
Malavika Chandra, David Heidt, Diane Simeone, Barbara McKenna, James Scheiman, and Mary-Ann Mycek
6628_69 European Conference on Biomedical Optics (ECBO) 2007
Malavika Chandra, Robert H. Wilson, James Scheiman, Diane Simeone, Barbara McKenna, Julianne Purdy, and Mary-Ann Mycek
7368_1G European Conference on Biomedical Optics (ECBO) 2009